Skip to content
Wells Fargo Analyst Maintains EqualWeight Rating for Amphastar Pharma and Increases Price Target to 44
On May 17, 2023, Jacob Hughes, a Wells Fargo analyst, has maintained Amphastar Pharma’s Equal-Weight rating and increased the price target from $40 to $44. Amphastar Pharmaceuticals is a publicly traded company that specializes in developing, manufacturing, marketing, and selling generic and proprietary injectable, inhalation, and intranasal products. The company’s stock symbol is AMPH, and it currently trades under NASDAQ at around $42.79 per share. In recent news, Amphastar Pharmaceuticals has announced that Jacob Liawatidewi, Executive V.P. of Corporate Administration Center, will be presenting at the Wells Fargo conference.
Financial Health
Healthy
Debt to equity ratio: Neutral
Price to earnings ratio: Strong Buy
Price to book ratio: Strong Buy
Show more
Social Sentiments
10:00 AM (UTC)
Date:17 May, 2023
0
Twitter Sentiment
0.6537
Stocktwits Sentiment
Show more
‘
Amphastar Pharmaceuticals Inc. (AMPH) Stock Analysis and Performance on May 17, 2023
On May 17, 2023, Amphastar Pharmaceuticals Inc. (AMPH) opened at $42.47, slightly lower than its previous close of $42.93. The day’s trading range was narrow, with the stock fluctuating between $42.40 and $42.47. The volume was relatively low, with only 29 shares traded compared to the average volume of 443,893 shares over the past three months.
AMPH has shown strong growth in recent years, with earnings growth of 44.78% for the past year and projected growth rates of 16.51% this year and 19.00% over the next five years. The company’s revenue also grew by 13.98% last year.
AMPH has a P/E ratio of 24.0, a price/sales ratio of 2.94, and a price/book ratio of 3.79, all in line with industry averages.
Competitors Valeant Pharmaceuticals International Inc. (BHCV) and Supernus Pharmaceuticals Inc. (SUPN) both saw slight declines in their stock prices on May 17, 2023.
AMPH’s next reporting date is August 9, 2023, with an EPS forecast of $0.56. The company had an annual revenue of $499.0M and an annual profit of $91.4M last year, with a net profit margin of 18.31%.
AMPH operates in the health technology sector, specifically in the pharmaceuticals industry. Its corporate headquarters are located in Rancho Cucamonga, California.
Amphastar Pharmaceuticals Inc (AMPH) Stock Outlook: Strong Financial Performance and Positive Analyst Consensus for Buying
On May 17, 2023, Amphastar Pharmaceuticals Inc (AMPH) had a median target price of $44.00, with a high estimate of $46.00 and a low estimate of $43.00, according to three analysts offering 12-month price forecasts. The current consensus among five investment analysts is to buy AMPH stock. The positive outlook for AMPH is likely due to the company’s strong financial performance in the current quarter, with earnings per share of $0.56 and sales of $136.8 million. Investors looking to capitalize on the positive outlook for AMPH may want to consider buying the stock before the company’s reporting date on August 09, 2023. However, it is important to note that investing in any stock carries inherent risks, and past performance does not guarantee future results.
